Clinical trial

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

NCT00385580

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-01-01

PhasePHASE2

Study timeline

Study start (unknown)2007-01-01Date precision: month

Registry last updated2013-04-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

dasatinibDRUG · verified · RxNorm: dasatinib

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

Mapped research locations

New YorkNew York, United States1 ChicagoIllinois, United States1 Los AngelesCalifornia, United States1 PhiladelphiaPennsylvania, United States1 BaltimoreMaryland, United States1 SeattleWashington, United States1 ParisFrance1 MontpellierFrance1 MadisonWisconsin, United States1 VillejuifFrance1 RomeItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00385580 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.